# BIONIKK (NCT02960906)

> A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

No report yet. It can be ordered.

- Drugs tested: nivolumab plus ipilimumab; nivolumab; pazopanib
- Indication: first-line metastatic clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02960906
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
- Conditions: Clear Cell Metastatic Renal Cell Carcinoma
- Interventions: Nivolumab; Ipilimumab; Pazopanib; Sunitinib
- Enrollment: 200
- Primary outcome: ORR evaluation according to molecular groups (ccRCC1 to 4) and assigned treatment

## Questions raised in the commentary

_Automated from all 27 indexed sources (Sep 2018 – Oct 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether molecular profiling can guide treatment choice
- Which molecular signatures may distinguish benefit from immunotherapy versus VEGF-targeted therapy
- Whether biomarker-guided treatment can be validated and implemented in routine practice

Also discussed: second-line treatment, IMDC criteria.

## Indexed commentary on BIONIKK so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 19
- YouTube: 4
- Podcasts: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=bionikk-nct02960906

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02960906", "email": "<work email>"}; the inbox owner confirms by the emailed link.